MIRA
INFORM REPORT
|
Report Date : |
30.08.2013 |
IDENTIFICATION DETAILS
|
Name : |
CHONGQING KERUI NANHAI PHARMACEUTICAL CO., LTD. |
|
|
|
|
Registered Office : |
12-07, |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
31.12.2011 |
|
|
|
|
Date of Incorporation : |
22.11.1995 |
|
|
|
|
Com. Reg. No.: |
500900000003539 |
|
|
|
|
Legal Form : |
Limited Liabilities Company |
|
|
|
|
Line of Business : |
Manufacturing and selling of oral liquid, tablets, capsules, granules, bulk drug. |
|
|
|
|
No. of Employees : |
295 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st 2013
|
Country Name |
Previous Rating (31.12.2012) |
Current Rating (31.03.2013) |
|
China |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
CHINA - ECONOMIC OVERVIEW
Since the late 1970s China has moved from a closed, centrally planned system to a more market-oriented one that plays a major global role - in 2010 China became the world's largest exporter. Reforms began with the phasing out of collectivized agriculture, and expanded to include the gradual liberalization of prices, fiscal decentralization, increased autonomy for state enterprises, creation of a diversified banking system, development of stock markets, rapid growth of the private sector, and opening to foreign trade and investment. China has implemented reforms in a gradualist fashion. In recent years, China has renewed its support for state-owned enterprises in sectors it considers important to "economic security," explicitly looking to foster globally competitive national champions. After keeping its currency tightly linked to the US dollar for years, in July 2005 China revalued its currency by 2.1% against the US dollar and moved to an exchange rate system that references a basket of currencies. From mid 2005 to late 2008 cumulative appreciation of the renminbi against the US dollar was more than 20%, but the exchange rate remained virtually pegged to the dollar from the onset of the global financial crisis until June 2010, when Beijing allowed resumption of a gradual appreciation. The restructuring of the economy and resulting efficiency gains have contributed to a more than tenfold increase in GDP since 1978. Measured on a purchasing power parity (PPP) basis that adjusts for price differences, China in 2010 stood as the second-largest economy in the world after the US, having surpassed Japan in 2001. The dollar values of China's agricultural and industrial output each exceed those of the US; China is second to the US in the value of services it produces. Still, per capita income is below the world average. The Chinese government faces numerous economic challenges, including: (a) reducing its high domestic savings rate and correspondingly low domestic demand; (b) sustaining adequate job growth for tens of millions of migrants and new entrants to the work force; (c) reducing corruption and other economic crimes; and (d) containing environmental damage and social strife related to the economy's rapid transformation. Economic development has progressed further in coastal provinces than in the interior, and by 2011 more than 250 million migrant workers and their dependents had relocated to urban areas to find work. One consequence of population control policy is that China is now one of the most rapidly aging countries in the world. Deterioration in the environment - notably air pollution, soil erosion, and the steady fall of the water table, especially in the North - is another long-term problem. China continues to lose arable land because of erosion and economic development. The Chinese government is seeking to add energy production capacity from sources other than coal and oil, focusing on nuclear and alternative energy development. In 2010-11, China faced high inflation resulting largely from its credit-fueled stimulus program. Some tightening measures appear to have controlled inflation, but GDP growth consequently slowed to near 9% for 2011. An economic slowdown in Europe is expected to further drag Chinese growth in 2012. Debt overhang from the stimulus program, particularly among local governments, and a property price bubble challenge policy makers currently. The government's 12th Five-Year Plan, adopted in March 2011, emphasizes continued economic reforms and the need to increase domestic consumption in order to make the economy less dependent on exports in the future. However, China has made only marginal progress toward these rebalancing goals.
Source
: CIA
Company name and address
CHONGQING KERUI
NANHAI PHARMACEUTICAL CO., LTD.
12-07, CENTURY EMPEROR BUILDING, NO. 38 JIANXIN NORTH ROAD
JIANGBEI DISTRICT, CHONGQING 400020 PR CHINA
TEL: 86 (0) 23-67797458
FAX: 86 (0) 23-67797453
EXECUTIVE SUMMARY
Date of Registration : november 22, 1995
REGISTRATION NO. : 500900000003539
LEGAL FORM : Limited liabilities company
REGISTERED CAPITAL : cny 30,000,000
staff :
295
BUSINESS CATEGORY : manufacturing
Revenue :
CNY 189,247,000 (AS OF DEC. 31,
2011)
EQUITIES :
CNY 71,841,000 (AS OF DEC. 31, 2011)
WEBSITE : www.keruinh.com
E-MAIL :
N/A
PAYMENT :
AVERAGE
MARKET CONDITION : COMPETITIVE
FINANCIAL CONDITION : fairly stable
OPERATIONAL TREND : fairly STEADY
GENERAL REPUTATION : AVERAGE
EXCHANGE RATE :
CNY 6.22 = USD 1
Adopted
abbreviations (as follows)
SC - Subject Company
(the company inquired by you)
N/A – Not available
CNY – China Yuan Ren
Min Bi
OPERATIONAL TREND & GENERAL
REPUTATION
This section aims at indicating the relative positions of SC in respect
of its operational trend & general reputation
Operational Trend:- General
Reputation:-
Upward Excellent
Steady Good
Fairly Steady Fairly
Good
Ordinary Average
Fair Fair
Stagnant Detrimental
Downward Not
known
Not known Not
yet be determined
LEGAL STATUS & HISTORY
SC was established
as a limited liabilities company of PRC with State Administration of Industry
& Commerce (SAIC) under registration No.: 500900000003539 on November 22, 1995.
SC’s Organization Code Certificate No.:
21390264-9
SC’s registered capital: cny 30,000,000
SC’s paid-in capital: cny 30,000,000
Registration Change Record:-
No significant changes of SC have been noted
in SAIC since its incorporation.
Current Co search indicates SC’s shareholders & chief executives are
as follows:-
|
Name of Shareholder (s) |
% of Shareholding |
|
Chongqing Kerui Pharmaceutical (Group)
Co., Ltd. |
55 |
|
Chongqing Xinyu Investment Group Co., Ltd. |
45 |
SC’s Chief Executives:-
|
Position |
Name |
|
Legal Representative and Chairman |
Shen Wenqiu |
|
General Manager |
Zou Shihong |
RECENT DEVELOPMENT
SC has got the certificate ISO9001.
SHAREHOLDER CHART &
BACKGROUND
Name %
of Shareholding
Chongqing Kerui Pharmaceutical (Group) Co.,
Ltd. 55
Chongqing Xinyu Investment Group Co., Ltd. 45
Chongqing Kerui Pharmaceutical (Group) Co., Ltd.
=========================================
Date of Registration: March 3, 1999
Registration No.: 500902000014562
Legal Form: Limited Liabilities
Company
Registered Capital: CNY 43,170,000
Address: Dashi Branch 2，Economics And
Technological Development Zone, Nan’An District, Chongqing
Tel: 86 (0) 23-62765066
Fax: 86 (0) 23-62756418
Chongqing Xinyu Investment Group Co., Ltd.
====================================
Date of Registration: July 4, 1997
Registration No.: 500900000001141
Legal Form: One-person Limited
Liability Company
Registered Capital: CNY 300,000,000
MANAGEMENT
Shen Wenqiu , Legal Representative and Chairman
-----------------------------------------------------------------------------
Ø
Gender: M
Ø
Qualification:
University
Ø
Working
experience (s):
At present, working in SC as legal representative and
chairman
Also working in Chongqing Kerui Pharmaceutical
(Group) Co., Ltd. as legal representative
Zou Shihong , General
Manager
-----------------------------------------------------
Ø
Gender: M
Ø
Age: 43
Ø
ID# 320121197008300037
Ø
Qualification:
University
Ø
Working
experience (s):
At present, working in SC as general manager
BUSINESS OPERATION
SC’s registered business scope includes planting,
purchasing and selling Chinese herbal medicines, goods import and export, manufacturing
oral liquid, tablets, capsules, granules, bulk drug, selling its owned
products.
SC is mainly
engaged in manufacturing and selling oral liquid, tablets, capsules, granules,
bulk drug.
SC’s products
mainly include: oral liquid, tablets, capsules, granules, bulk drug.
SC sources its materials 100% from domestic market, mainly Sichuan. SC sells 77% of its products in domestic market, and 23% to overseas market, mainly Mid East, Southeast Asia, etc.
The buying terms
of SC include Check, T/T and Credit of 30-60 days. The payment terms of SC
include T/T, L/C and Credit of 30-60 days.
Staff & Office:
--------------------------
SC is known
to have approx. 295 staff at
present.
SC owns an area as
its operating office & factory of approx. 11,000 sq. meters at the heading
address.
RELATED COMPANY
SC is not known to have any subsidiary at present.
PAYMENT
Overall payment appraisal:
( ) Excellent ( ) Good (X) Average ( ) Fair ( ) Poor ( ) Not yet be determined
The appraisal serves as a reference to reveal SC's payments habits and
ability to pay. It is based on the 3
weighed factors: Trade payment experience (through current enquiry with SC's
suppliers), our delinquent payment and our debt collection record concerning
SC.
Trade payment experience: SC did not
provide any name of trade/service suppliers and we have no other sources to
conduct the enquiry at present.
Delinquent payment record: None in our
database.
Debt collection record: No overdue amount
owed by SC was placed to us for collection within the last 6 years.
BANKING
The bank
information of SC is not filed in SAIC.
FINANCIALS
Balance Sheet
|
Unit: CNY’000 |
As
of Dec. 31, 2010 |
As
of Dec. 31, 2011 |
|
16,564 |
1,534 |
|
|
Notes receivable |
121 |
6,889 |
|
Accounts
receivable |
3,335 |
10,322 |
|
Advances to
suppliers |
3,210 |
4,600 |
|
Interest
receivable |
30 |
77 |
|
Other receivable |
12,150 |
20,271 |
|
Inventory |
38,921 |
91,680 |
|
Non-current
assets within one year |
0 |
0 |
|
Other current
assets |
0 |
0 |
|
|
------------------ |
------------------ |
|
Current assets |
74,331 |
135,373 |
|
Fixed assets |
39,938 |
80,986 |
|
Construction in
progress |
22,920 |
0 |
|
Intangible
assets |
5,721 |
5,676 |
|
Long-term prepaid
expenses |
0 |
0 |
|
Deferred income
tax assets |
2,529 |
0 |
|
Other
non-current assets |
258 |
1,162 |
|
|
------------------ |
------------------ |
|
Total assets |
145,697 |
223,197 |
|
|
============= |
============= |
|
Short-term loans |
48,000 |
71,000 |
|
Notes payable |
0 |
0 |
|
Accounts payable |
8,520 |
13,818 |
|
Wages payable |
2,904 |
4,986 |
|
Taxes payable |
-736 |
-294 |
|
Advances from
clients |
3,889 |
2,931 |
|
Other payable |
17,106 |
44,128 |
|
Other current
liabilities |
3,407 |
787 |
|
|
------------------ |
------------------ |
|
Current
liabilities |
83,090 |
137,356 |
|
Non-current
liabilities |
15,000 |
14,000 |
|
|
------------------ |
------------------ |
|
Total
liabilities |
98,090 |
151,356 |
|
Equities |
47,607 |
71,841 |
|
|
------------------ |
------------------ |
|
Total
liabilities & equities |
145,697 |
223,197 |
|
|
============= |
============= |
Income Statement
|
Unit: CNY’000 |
As of Dec. 31,
2010 |
As of Dec. 31,
2011 |
|
Revenue |
82,640 |
189,247 |
|
Cost of sales |
62,423 |
144,834 |
|
Taxes and surcharges |
366 |
63 |
|
Sales expense |
2,460 |
3,874 |
|
Management expense |
9,220 |
13,707 |
|
Finance expense |
2,979 |
7,498 |
|
Non-business
income |
3,908 |
8,304 |
|
Non-business expenditure |
87 |
466 |
|
Profit before
tax |
8,669 |
24,974 |
|
Less: profit tax |
1,314 |
2,540 |
|
7,355 |
22,434 |
Important Ratios
=============
|
|
As
of Dec. 31, 2010 |
As
of Dec. 31, 2011 |
|
*Current ratio |
0.89 |
0.99 |
|
*Quick ratio |
0.43 |
0.32 |
|
*Liabilities
to assets |
0.67 |
0.68 |
|
*Net profit
margin (%) |
8.90 |
11.85 |
|
*Return on
total assets (%) |
5.05 |
10.05 |
|
*Inventory /
Revenue ×365 |
172 days |
177 days |
|
*Accounts receivable/
Revenue ×365 |
15 days |
20 days |
|
*
Revenue/Total assets |
0.57 |
0.85 |
|
* Cost of
sales / Revenue |
0.76 |
0.77 |
FINANCIAL COMMENTS
PROFITABILITY:
FAIRLY GOOD
l
The revenue of SC appears average, and it was
rising in 2011.
l
SC’s net profit margin is fairly good in both
years.
l
SC’s return on total assets is fairly good in both
years.
l
SC’s cost of sales is average, comparing with its
revenue.
LIQUIDITY: FAIR
l
The current ratio of SC is maintained in a fair
level.
l
SC’s quick ratio is maintained in a poor level.
l
The inventory of SC appears large.
l
The accounts receivable of SC is maintained in an
average level.
l
The short-term loans of SC appear large.
l
SC’s revenue is in a fair level, comparing with the
size of its total assets.
LEVERAGE: AVERAGE
l
The debt ratio of SC is average.
l
The risk for SC to go bankrupt is average.
Overall financial
condition of the SC: Fairly Stable.
CONCLUSIONS
SC is considered medium-sized in its line with fairly stable financial
conditions. The large amount of inventory and short-term loans may be a threat
to SC’s financial condition.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.67.71 |
|
UK Pound |
1 |
Rs.105.14 |
|
Euro |
1 |
Rs.90.03 |
INFORMATION DETAILS
|
Report Prepared
by : |
MNL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.